Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien(Maidstone Hospital), Nely Wigler(Tel Aviv Sourasky Medical Center), Moshe Inbar(Tel Aviv Sourasky Medical Center), R. Rosso(Associazione Italiana Di Oncologia Medica), Eva‐Maria Grischke(Heidelberg University), Armando Santoro(Fondazione Humanitas per la Ricerca), Raphael Catane(Shaare Zedek Medical Center), D G Kieback(Maastricht University), Piotr Tomczak(Hematology\Oncology Clinic), Stephen P. Ackland(Mater Misericordiae Hospital), F. Orlandi(Hospital Dipreca), L. Mellars(Merck Biopharma Co., Ltd. (Japan)), Leila Alland(Merck Biopharma Co., Ltd. (Japan)), Craig Tendler(Merck Biopharma Co., Ltd. (Japan))
Annals of Oncology
March 1, 2004
10.1093/annonc/mdh097
Cited by 1,711Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis